Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), would like to update shareholders on its operations in Mexico. On October 30, 2018, regulations for CBD products were published by COFEPRIS. The regulations include that products made from hemp are industrial products that can be traded as cosmetics, supplement foods and herbal products. CBD medicines were also included in the regulations and will require clinicals and proper protocols.
Isodiol established operations in Mexico in 2017 and has since signed distribution agreements with companies specializing in the distribution of pharmaceutical products across Mexico. The Company has also developed a sales team to cover the government and private sectors for medical, veterinary, laboratory and the cosmetic sales channels. The Company anticipates sales to commence in the first quarter of 2019 and will continue to educate health professionals in the coming months on Isoderm Direct Effect Technology and its approved CBD as an Active Pharmaceutical Ingredient (API) from BSPG Labs, through seminars and associations with a focus on medical conditions including Epilepsy, Parkinson’s and Alzheimer’s.
The Company also applauds US Senator Mitch McConnell for his continued support of the Farm Bill, which is anticipated to fully legalize hemp in the United States for the first time since 1937. Hemp historically has many uses including medicines, clothing, cooking oil, soaps, lotions as well as building materials, animal bedding and biofuels1. “It’s interesting to think about what it could be,” McConnell said. “I don’t want to overstate this, I don’t know whether it’s going to be the next tobacco or not, but I do think it has a lot of potential2,” he added.
On Friday, McConnell announced that completing the work of the new farm bill is one of his top priorities when Congress reconvenes. When discussing the legalization of hemp being included in the Farm Bill, McConnell said, “If there is a Farm Bill, it will be in there, I guarantee that3.” The bill is also anticipated to clarify legality of derivatives such as cannabidiol, also known as CBD, from the hemp plant.
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.